What are the clinical implications of NPM1 mutations in patients with acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Mutations in NPM1 are associated with increased response to chemotherapy in patients with a normal karyotype. [31] In a study by Thiede et al of FLT3 and NPM1 in 1485 patients with AML, analysis of the clinical impact in 4 groups (NPM1 and FLT3-ITD single mutants, double mutants, and wild-type [wt] for both) revealed that patients having only an NPM1 mutation (without a FLT3 -ITD) had a significantly better overall and disease-free survival and a lower cumulative incidence of relapse. [32] Analysis of NPM1 is commercially available.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!